Xynomic Pharmaceuticals Stock

xynomicpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $21.8MM

Xynomic Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates.

Register To Buy and Sell Shares

For more details on financing and valuation for Xynomic Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Xynomic Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Xynomic Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Yinglin Mark Xu
Co-Founder, Chief Executive Officer, President & Chairman
Chasey Zhang
Vice President, Global Strategic Sourcing
Jason Wu Ph.D
Co-Founder & Chief Operating Officer
Jinwei Kou
Interim Chief Accounting Officer
Yong Cui Ph.D
Vice President, CMC

News Highlights

Xynomic Pharma Completes Series B Crossover Financing |FinSMEs
Xynomic Pharma, a Dover, DE- and Shanghai, China-based oncology drug development company, completed a Series B crossover financing of undisclosed amount.
Xynomic Pharma Completes Series B Crossover Financing, Starts Four Pivotal Trials in Renal Cell Carcinoma (RCC) and Lymphoma, and Opens a R&D Center
/PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug development company, today announced that it has completed Series B Crossover...
Updated on: Nov 28, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.